Spectrum Pharmaceuticals, Inc.

NasdaqCM:SPPI Aktierapport

Börsvärde: US$209.9m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Spectrum Pharmaceuticals Förvaltning

Förvaltning kriterier kontrolleras 1/4

Spectrum Pharmaceuticals VD är Tom Riga, utsedd i Dec 2021, har en mandatperiod på 1.67 år. totala årliga ersättningen är $ 2.60M, bestående av 25% lön 75% bonusar, inklusive företagsaktier och optioner. äger direkt 0.26% av företagets aktier, värda $ 537.60K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 1.5 år respektive 2.5 år.

Viktig information

Tom Riga

Verkställande direktör

US$2.6m

Total ersättning

VD-lön i procent25.04%
Anställning som VD1.7yrs
Ägande av VD0.3%
Ledningens genomsnittliga anställningstid1.5yrs
Styrelsens genomsnittliga mandatperiod2.5yrs

Senaste uppdateringar av ledningen

Recent updates

Analysartikel • May 14

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Shareholders in Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) may be thrilled to learn that the analysts have just...
Analysartikel • May 12

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) investors will be delighted, with the company turning in some strong...
Seeking Alpha • Sep 20

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

US FDA scientists are concerned about the data Spectrum Pharmaceuticals (NASDAQ:SPPI) has provided to support its drug poziotinib for non-small cell lung cancer ahead of an advisory committee meeting on Thursday. Shares are down 28% in Tuesday morning trading. In a briefing document, the FDA scientists state the data provided shows a low overall response rate (ORR) with minimal duration of response (DOR). ORR was 28% while median DOR was 5.1 months. In addition, they say the safety profile is poor in that at the proposed dosage, 57% of patients experienced dose reductions and 85% of patients had grade 3-4 adverse events. Also, the FDA team faults Spectrum (SPPI) for what it calls inadequate dosage optimization since the company has proposed two different doses for accelerated approval and the planned confirmatory trial. "Confirmation of benefit will be significantly delayed given that confirmatory trial has not begun enrolling patients." Poziotinib is an oral tyrosine kinase inhibitor that inhibits the activity of epidermal growth factor receptor (EGFR [HER1], HER2, and HER4) kinases. Seeking Alpha's Quant Rating views Spectrum (SPPI) as a hold.
Analysartikel • Sep 16

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Sep 09

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals (NASDAQ:SPPI) stock jumped 10.4% afterhours on Friday after the U.S. Food and Drug Administration approved its Rolvedon injection. The injection is used to treat chemotherapy-induced neutropenia (abnormally low count of a type of neutrophils). SPPI said the FDA's nod marks the first novel long-acting GCSF (LA-GCSF) product approval in over 20 years. The company plans to commercially launch the injection in Q4. Shares of SPPI have fallen 18.2% YTD.
Seeking Alpha • Aug 21

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

We are circling back on a small biopharma named Spectrum Pharmaceuticals for the first time in a year and a half today. Spectrum has turned into a soap opera since then with two departures from the C-Suite, a CRL, and a significant workforce reduction. However, the company still is pushing two compounds towards potential FDA approval this year. An investment analysis follows in the paragraphs below. "Even as a solid rock is unshaken by the wind, so are the wise unshaken by praise or blame."― Dhammapada We last posted an article on Spectrum Pharmaceuticals (SPPI) back in March of 2021. At that time, we declined any investment recommendation on the shares but did promise to circle back on this name as its story developed. The company reported second-quarter results earlier this month and I have gotten a question or two from Seeking Alpha followers recently. Therefore, we will revisit this small biopharma company via the analysis below. Seeking Alpha Company Overview: Spectrum Pharmaceuticals focuses on developing and commercializing novel and targeted drug products with a primary focus in oncology. The company is headquartered just outside of Las Vegas. The stock currently trades around $1.25 a share and sports an approximate market capitalization of $250 million. Recent Developments: The company has been a non-stop soap opera since we last looked in on it. Its primary asset is ROLONTIS (eflapegrastim). Spectrum had submitted a marketing application on it for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs. This candidate has had a rocky ride, to say the least, towards FDA approval. First, the inspection of the manufacturing facility where ROLONTIS was to be made in South Korea by partner Hanmi was delayed thanks to the pandemic. March Company Presentation Then in August of 2021, the FDA slapped Spectrum's Biologics License Application or BLA with a Complete Response Letter or CRL. The CRL cited deficiencies related to manufacturing and indicated that a re-inspection will be necessary. Then in December of last year, the company announced its CEO was retiring which was followed by resignation of its CFO in February of this year. In between those management losses, Spectrum announced a restructuring that resulted in approximately 30% of its workforce being let go. The company also halted development of early-stage drug candidates to focus solely on pushing poziotinib and ROLONTIS across the finish line. These measures were projected to reduce annual cash burn by 20% to 25% and push the company's 'cash runway' into 2023. The company did resubmit its BLA for ROLONTIS in April and the FDA is scheduled to make a decision on its application on September 9th. January 2021 Company Presentation The FDA completed re-inspection of the manufacturing facility for ROLONTIS in August. Chemo-induced neutropenia impacts just over one million individuals in the United States. ROLONTIS would be the first drug in its class approved for this indication since Neulasta got the green light from the FDA in 2002. March Company Presentation March Company Presentation The approval path for poziotinib has been much smoother to this point. The compound is targeting patients with previously treated, locally advanced or metastatic non-small cell lung cancer, harboring HER2 exon 20 insertion mutations. This drug candidate is an orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. Poziotinib has fast track designation and is on an accelerated approval pathway for this indication. The NDA was submitted some ago has a PDUFA date of November 24th of this year. It is important to note Poziotinib has a much smaller potential market than ROLONTIS and the company will have to demonstrate the compound has an overall risk benefit and clinical relevance based on its 'ZENITH' study to the FDA to garner approval. A randomized confirmatory trial is currently ongoing. A critical phase 2 trial in 2nd line NSCLC patients with EGFR exon 20 mutations around Poziotinib did not meet its primary endpoint of ORR in one of its cohorts early in 2020. Analyst Commentary & Balance Sheet: Since second quarter results posted, B. Riley Financial ($4 price target), H.C. Wainwright ($10 price target) and JMP Securities ($4 price target) have all reiterated Buy ratings on SPPI.
Seeking Alpha • Aug 10

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals (NASDAQ:SPPI) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.10 (+60.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 2 years, SPPI has beaten EPS estimates 38% of the time and has beaten revenue estimates 13% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward.
Analysartikel • Jun 04

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 25

Spectrum Pharmaceuticals: Some Last Words

A spate of bad luck has destroyed SPPI stock. CEO and CFO have both resigned. Even if, somehow, ROLONTIS gets approved, they don't have the cash to commercialize.
Analysartikel • Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 12

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

SPPI received a surprise CRL for rolontis. This could be resolved before the year is out, but there is no real clarity. The company does have enough cash to last it for a year or more.
Seeking Alpha • Jul 29

Spectrum's Big Approval: Any Day Now

The FDA completed the inspection of Hanmi's Korean facility almost a month ago. Approval should happen any day now. Rolontis is targeting a $3bn+ market.
Analysartikel • May 31

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Feb 12

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysartikel • Dec 21

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

A look at the shareholders of Spectrum Pharmaceuticals, Inc. ( NASDAQ:SPPI ) can tell us which group is most powerful...

Analys av ersättningar till VD

Hur har Tom Riga:s ersättning förändrats jämfört med Spectrum Pharmaceuticals:s resultat?
DatumTotal ersättningLönFöretagets resultat
Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$3mUS$650k

-US$78m

Sep 30 2022n/an/a

-US$106m

Jun 30 2022n/an/a

-US$117m

Mar 31 2022n/an/a

-US$138m

Dec 31 2021US$4mUS$550k

-US$158m

Sep 30 2021n/an/a

-US$169m

Jun 30 2021n/an/a

-US$184m

Mar 31 2021n/an/a

-US$166m

Dec 31 2020US$3mUS$550k

-US$171m

Sep 30 2020n/an/a

-US$162m

Jun 30 2020n/an/a

-US$140m

Mar 31 2020n/an/a

-US$136m

Dec 31 2019US$4mUS$550k

-US$135m

Sep 30 2019n/an/a

-US$148m

Jun 30 2019n/an/a

-US$191m

Mar 31 2019n/an/a

-US$147m

Dec 31 2018US$5mUS$500k

-US$127m

Sep 30 2018n/an/a

-US$102m

Jun 30 2018n/an/a

-US$51m

Mar 31 2018n/an/a

-US$87m

Dec 31 2017US$1mUS$420k

-US$101m

Ersättning vs marknad: Tom s total kompensation ($USD 2.60M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 1.67M ).

Ersättning vs inkomst: Ersättningen från Tom har varit i linje med företagets resultat under det senaste året.

VD OCH KONCERNCHEF

Tom Riga (48 yo)

1.7yrs
Anställning
US$2,595,633
Kompensation

Mr. Thomas J. Riga, also known as Tom, is President, Chief Executive Officer and Director at Spectrum Pharmaceuticals, Inc. since December 30, 2021. He had been the Chief Operating Officer at Spectrum Phar...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Thomas Riga
President1.7yrsUS$2.60m0.26%
$ 537.6k
Nora Brennan
Executive VP & CFO1.3yrsUS$46.25k0.051%
$ 108.0k
Keith McGahan
Executive VP5.5yrsUS$1.50m0.11%
$ 239.2k
Michael Grabow
Executive VP & Chief Business Officerless than a yearinga uppgifteringa uppgifter
1.5yrs
Genomsnittlig anställningstid
48yo
Genomsnittlig ålder

Erfaren ledning: SPPI s ledningsgrupp anses inte vara erfaren ( 1.5 års genomsnittlig anställningstid), vilket föreslår ett nytt team.

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Thomas Riga
President1.7yrsUS$2.60m0.26%
$ 537.6k
Seth H. Fischer
Independent Director3.3yrsUS$178.83k0.0020%
$ 4.2k
William Ashton
Independent Chairman of the Board5.5yrsUS$202.58k0.021%
$ 43.9k
Jeffrey Vacirca
Independent Director4.8yrsUS$181.33k0.13%
$ 278.4k
Brittany Bradrick
Independent Director1.3yrsUS$158.53kinga uppgifter
Juhyun Lim
Director1.4yrsUS$183.93k0.0023%
$ 4.9k
2.5yrs
Genomsnittlig anställningstid
53.5yo
Genomsnittlig ålder

Erfaren styrelse: SPPI s styrelse anses inte vara erfaren ( 2.5 års genomsnittlig mandatperiod), vilket föreslår en ny styrelse.

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2023/08/02 23:15
Aktiekurs vid dagens slut2023/07/31 00:00
Intäkter2023/03/31
Årlig intjäning2022/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Spectrum Pharmaceuticals, Inc. bevakas av 9 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
David BuckB. Riley Securities, Inc.
Alethia YoungCantor Fitzgerald & Co.
Reni BenjaminCitizens JMP Securities, LLC